Intuitive’s stock slid in after-hours trading today after the company posted Q3 results that exceeded analysts’ expectations on profits but fell short on sales. Even if they had beat The Street on both counts, it’s not clear investors would have reacted any differently — just look at what happened to Intuitive’s stock price under that exact scenario after Q2.
In Q2, the company said bariatric procedure growth slowed due to patient interest in weight loss drugs.
Related: Analysts expect minor GLP-1 impact on insulin pumps, but a boost for CGMs
“Bariatric procedures represent between four and 5% of total global procedures,R…